Apriem Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Apriem Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-300	Closed	-$12K	–	668
2016 Q2	$12K	Buy	+300	New	+$12.5K	﹤0.01%	397
2015 Q3	–	Sell	-220	Closed	-$12K	–	646
2015 Q2	$12K	Buy	+220	New	+$11.7K	﹤0.01%	402

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Apriem Advisors's JUNO Position: Q3 2016 in Review

Apriem Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 300 shares — an estimated $12K sold.

Apriem Advisors first reported a position in JUNO in Q2 2015 and held it in 2 quarters. The position peaked at $12K in Q2 2016. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

Apriem Advisors reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Apriem Advisors sold 300 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $12K.
Apriem Advisors first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
Apriem Advisors's Juno Therapeutics, Inc. position peaked at $12K in Q2 2016.
169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on Apriem Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.